scholarly journals Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy

2015 ◽  
Vol 136 (2) ◽  
pp. 351-362 ◽  
Author(s):  
Jana Zschüntzsch ◽  
Yaxin Zhang ◽  
Florian Klinker ◽  
Gregor Makosch ◽  
Lars Klinge ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Mouse Model ◽  
Immunoglobulin G ◽  
Human Immunoglobulin ◽  
Disease Course ◽  
Early Disease ◽  
Human Immunoglobulin G

scholarly journals Human immunoglobulin G for experimental treatment of Duchenne muscular dystrophy

2014 ◽  
Vol 178 ◽  
pp. 132-133
Author(s):  
J. Zschüntzsch ◽  
P. Jouvenal ◽  
Y. Zhang ◽  
F. Klinker ◽  
M. Tiburcy ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Immunoglobulin G ◽  
Experimental Treatment ◽  
Human Immunoglobulin ◽  
Human Immunoglobulin G

Cleavage of Human Immunoglobulin G by Treponema denticola

Anaerobe ◽  
2001 ◽  
Vol 7 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Daniel Grenier ◽  
Denis Mayrand
Keyword(s):  
Immunoglobulin G ◽  
Human Immunoglobulin ◽  
Treponema Denticola ◽  
Human Immunoglobulin G

scholarly journals In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Menglong Chen ◽  
Hui Shi ◽  
Shixue Gou ◽  
Xiaomin Wang ◽  
Lei Li ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Mouse Model ◽  
Genome Editing ◽  
Large Scale ◽  
Gene Editing ◽  
High Efficiency ◽  
Muscle Fibers ◽  
Muscle Cells

Abstract Background Mutations in the DMD gene encoding dystrophin—a critical structural element in muscle cells—cause Duchenne muscular dystrophy (DMD), which is the most common fatal genetic disease. Clustered regularly interspaced short palindromic repeat (CRISPR)-mediated gene editing is a promising strategy for permanently curing DMD. Methods In this study, we developed a novel strategy for reframing DMD mutations via CRISPR-mediated large-scale excision of exons 46–54. We compared this approach with other DMD rescue strategies by using DMD patient-derived primary muscle-derived stem cells (DMD-MDSCs). Furthermore, a patient-derived xenograft (PDX) DMD mouse model was established by transplanting DMD-MDSCs into immunodeficient mice. CRISPR gene editing components were intramuscularly delivered into the mouse model by adeno-associated virus vectors. Results Results demonstrated that the large-scale excision of mutant DMD exons showed high efficiency in restoring dystrophin protein expression. We also confirmed that CRISPR from Prevotella and Francisella 1(Cas12a)-mediated genome editing could correct DMD mutation with the same efficiency as CRISPR-associated protein 9 (Cas9). In addition, more than 10% human DMD muscle fibers expressed dystrophin in the PDX DMD mouse model after treated by the large-scale excision strategies. The restored dystrophin in vivo was functional as demonstrated by the expression of the dystrophin glycoprotein complex member β-dystroglycan. Conclusions We demonstrated that the clinically relevant CRISPR/Cas9 could restore dystrophin in human muscle cells in vivo in the PDX DMD mouse model. This study demonstrated an approach for the application of gene therapy to other genetic diseases.

Fractionation of human immunoglobulin G by chromatography on Remazol Yellow GGL-Sepharose

1982 ◽  
Vol 10 (2) ◽  
pp. 104-104 ◽  
Author(s):  
PETER G. H. BYFIELD ◽  
SUE COPPING ◽  
WILLIAM A. BARTLETT
Keyword(s):  
Immunoglobulin G ◽  
Human Immunoglobulin ◽  
Human Immunoglobulin G
Sign in / Sign up

Export Citation Format

Share Document